Axitinib

Drug Profile

Axitinib

Alternative Names: AG-013736; AG-13,736; Inlyta

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Merck Sharp & Dohme; Netherlands Cancer Institute; Pfizer; SCRI Development Innovations; SFJ Pharmaceuticals; University of Texas M. D. Anderson Cancer Center; University of Wisconsin-Madison
  • Class Antineoplastics; Imidazoles; Indazoles; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma
  • Phase II Carcinoid tumour; Colorectal cancer; Glioblastoma; Non-small cell lung cancer; Prostate cancer
  • Phase I Solid tumours
  • Discontinued Breast cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Pancreatic cancer; Thyroid cancer

Most Recent Events

  • 02 Jun 2017 Updated efficacy and adverse events data from a phase Ib trial in Renal cell carcinoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 Preliminary efficacy and adverse event data from a phase Ib trial in Solid tumours presented at the at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Jun 2017 Pfizer completes the AXIPAN phase II trial in Renal cell carcinoma (Neoadjuvant therapy) in France (NCT02597322)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top